User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

(2015) Rhonda Bentley-Lewis et al.   AMERICAN HEART JOURNAL

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

(2015) G. H. Daniels et al.   DIABETES OBESITY & METABOLISM

Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice

(2015) Kristy M. Heppner et al.   DIABETOLOGIA

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015 —EXECUTIVE SUMMARY

(2015) Yehuda Handelsman et al.   Endocrine Practice

AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2015

(2015) Alan J. Garber et al.   Endocrine Practice

Five-Year Efficacy and Safety Data of Exenatide Once Weekly

(2015) Carol H. Wysham et al.   MAYO CLINIC PROCEEDINGS

Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes

(2014) Joseph M. Tibaldi   ADVANCES IN THERAPY

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

(2014) Angelo Avogaro et al.   Current Diabetes Reports

GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK

(2014) D. Beiroa et al.   DIABETES

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

(2014) Michaela Diamant et al.   DIABETES CARE

Is insulin the most effective injectable antihyperglycaemic therapy?

(2014) J. B. Buse et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials

(2014) Matteo Monami et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes

(2014) William M. Steinberg et al.   PANCREAS

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

(2014) L. Li et al.   BMJ-British Medical Journal

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

(2014) Michaela Diamant et al.   Lancet Diabetes & Endocrinology

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

(2013) Steven P. Marso et al.   AMERICAN HEART JOURNAL

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction

(2013) Daniel Lorber   Cardiovascular Therapeutics

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

(2013) D.R. Owens et al.   DIABETES & METABOLISM

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

(2013) B. Wang et al.   DIABETES OBESITY & METABOLISM

Incretin hormones and the satiation signal

(2013) J J Holst   INTERNATIONAL JOURNAL OF OBESITY

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

(2012) Vanita R. Aroda et al.   CLINICAL THERAPEUTICS

Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success

(2011) Richard B. Aguilar   CLINICAL THERAPEUTICS

Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment

(2011) Mette Bøgelund et al.   CURRENT MEDICAL RESEARCH AND OPINION

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

(2011) J. J. Holst et al.   DIABETES CARE

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

(2010) Caroline M. Apovian et al.   AMERICAN JOURNAL OF MEDICINE

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

(2010) C. J. Girman et al.   DIABETES OBESITY & METABOLISM

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Minireview: Finding the Sweet Spot: PeripheralVersusCentral Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis

(2009) Diana L. Williams   ENDOCRINOLOGY

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA